CT-Guided Stereotactic Body Radiation Therapy with Motion Tracking for Localized Prostate Cancer Treatment ILLUSION Trial

What this Trial Is About

Researchers are evaluating the side effects and effectiveness of computed tomography CT-guided stereotactic body radiation therapy SBRT with intrafraction motion monitoring for treating men with localized prostate cancer that has not spread. This study aims to determine the acute and late urinary and bowel side effects, patient-reported quality of life, and 5-year biochemical recurrence-free survival. The trial also assesses prostate motion during treatment to improve targeting precision. Participants receive CT-guided SBRT with intrafraction motion monitoring over 5 treatment sessions, typically given every other day or on consecutive days if needed. Imaging such as CT and MRI, along with blood sample collection, are performed throughout the study. The intrafraction motion monitoring helps track prostate movement during radiation to target the tumor more precisely and potentially reduce side effects. During the study, participants undergo regular follow-up visits at 1 and 3 months after treatment, then every 3 months for the first year, every 6 months for at least 5 years, and annually thereafter. Assessments include physician-scored urinary and gastrointestinal toxicities, patient questionnaires on quality of life, imaging scans, and blood tests. The main outcome measures focus on acute and late side effects, quality of life changes, cancer recurrence, and prostate motion during treatment.

Computed Tomography-Guided Stereotactic Body Radiation Therapy With Intrafraction Motion Monitoring for the Treatment of Localized Prostate Cancer, ILLUSION Trial